Your browser doesn't support javascript.
loading
Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave.
Yamamoto, Shohei; Matsuda, Kouki; Maeda, Kenji; Horii, Kumi; Okudera, Kaori; Oshiro, Yusuke; Inamura, Natsumi; Takeuchi, Junko S; Konishi, Maki; Ozeki, Mitsuru; Mizoue, Tetsuya; Sugiyama, Haruhito; Aoyanagi, Nobuyoshi; Mitsuya, Hiroaki; Sugiura, Wataru; Ohmagari, Norio.
Affiliation
  • Yamamoto S; Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: syamamoto@hosp.ncgm.go.jp.
  • Matsuda K; Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Maeda K; Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan.
  • Horii K; Infection Control Office, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
  • Okudera K; Infection Control Office, Kohnodai Hospital of the National Center for the Global Health and Medicine, Chiba, Japan.
  • Oshiro Y; Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
  • Inamura N; Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
  • Takeuchi JS; Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Konishi M; Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ozeki M; Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
  • Mizoue T; Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: mizoue@hosp.ncgm.go.jp.
  • Sugiyama H; Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
  • Aoyanagi N; Kohnodai Hospital of the National Center for the Global Health and Medicine, Chiba, Japan.
  • Mitsuya H; Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Sugiura W; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Int J Infect Dis ; 128: 347-354, 2023 Mar.
Article in En | MEDLINE | ID: mdl-36693493
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Int J Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2023 Document type: Article Country of publication: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Int J Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2023 Document type: Article Country of publication: Canada